Brolucizumab: a novel anti-VEGF humanized single-chain antibody fragment for treating w-AMD
Authors:
- 24 April 2021
- journal article
- research article
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 21 (5) , 553-561
Abstract
Wet age-related macular degeneration (w-AMD) represents the leading cause of visual impairment in the elderly in the developed countries. Intravitreal antivascular endothelial growth factor (VEGF) ...Keywords
Funding Information
- funded
This publication has 53 references indexed in Scilit:
- TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASESRetina, 2015
- Roles of VEGF-A signalling in development, regeneration, and tumoursThe Journal of Biochemistry, 2014
- Recent developments in the treatment of age-related macular degenerationJournal of Clinical Investigation, 2014
- Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysisThe Lancet Global Health, 2014
- Author replyOphthalmology, 2014
- Altered Expression of the Poly(ADP-Ribosyl)ation Enzymes in Uveal Melanoma and Regulation ofPARGGene Expression by the Transcription Factor ERMInvestigative Ophthalmology & Visual Science, 2012
- Age-related macular degenerationThe Lancet, 2012
- Metabolic physiology in age related macular degenerationProgress in Retinal and Eye Research, 2011
- Generic Approach for the Generation of Stable Humanized Single-chain Fv Fragments from Rabbit Monoclonal AntibodiesJournal of Biological Chemistry, 2010
- Pegaptanib sodium for the treatment of neovascular age-related macular degeneration: A reviewClinical Therapeutics, 2006